BEUDAMED
    FDA PMA FDA Class 3 Approved 🇺🇸 United States

    Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay

    PMA: P210001 · Supplement: S002 · Decision Jun 16, 2022
    View on FDA
    Classifications
    1
    FEI Numbers
    1
    Registration Numbers
    1

    Basic Information

    Device Name
    Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay
    Trade Name
    VENTANA MMR RxDx Panel
    PMA Number
    P210001
    Supplement Number
    S002
    Device Class
    FDA Class 3
    Product Code
    QNH
    Generic Name
    Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay
    Regulation Number
    864.1860
    Medical Specialty
    Hematology
    Advisory Committee
    Pathology
    Decision
    Approved
    Decision Code
    APPR
    Decision Date
    June 16, 2022
    Date Received
    December 20, 2021
    Supplement Type
    Normal 180 Day Track
    Supplement Reason
    Labeling Change - Indications/instructions/shelf life/tradename
    Expedited Review
    N

    Advisory Committee Statement

    Approval for the VENTANA MMR RxDx Panel as a companion diagnostic for identifying MMR proficient (pMMR) patients with endometrial cancer for treatment with KEYTRUDA in combination with LENVIMA.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    QNH Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay